Table 1 Comparison of clinicopathological properties of cases (HIV+) and controls (HIV−)
From: Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART?
HIV positive | HIV negative | |
n | 9 | 27 |
Median age | 45 years | 48 years |
(range 32–58) | (range 30–55) | |
Adenocarcinoma | 66% | 70% |
Stage IV disease | 66% | 70% |
ECOG performance status <2 at presentation | 22% | 52% |
(range 1–4) | (range 1–4) | |
Treated with chemotherapy | 88% | 66% |
Median number of cycles of chemotherapy | 3.5 | 4 |
(range 1–6) | (range 1–6) | |
Median overall survival | 4 months | 4 months |
(range 2–15+) | (range 1–24+) | |
Cancer-related deaths | 77% | 74% |
